Serotonergic approaches in the development of novel antipsychotics. Export

@article{citeulike:3100636, abstract = {Schizophrenia is a chronic, debilitating neuropsychological disease characterised by positive, negative, and cognitive deficits. In recent years, new pharmacological treatment strategies have been developed to treat the sequalae of schizophrenia based upon more selective receptor activity profiles in the hope that treatment efficacy can be increased without inducing the side-effect profiles seen with current available therapies. One such strategy involves the development of combined (partial) 5-HT(1A) agonists and D(2) receptor (partial) antagonists such as bifeprunox, SLV313, F15063 and SSR-181507 in an attempt to increase therapeutic efficacy of all symptom domains whilst alleviating adverse side effects. Other novel drugs including SLV310 and SLV314 combine selective serotonin reuptake inhibition (SSRI) functionality with D(2) receptor antagonism in an attempt to not only improve schizophrenic symptoms, but to also relieve other affective disorders intricately linked with the disorder. The main scope of this review will evaluate the major preclinical and clinical pharmacological findings concerning the aforementioned strategies and pharmacological agents, and compare their therapeutic potential with currently available antipsychotics; however, recent developments at other emerging serotonergic targets such as 5-HT(2C), 5-HT(6) and 5-HT(7) receptors will also be considered.}, address = {Institute of Neuroscience, School of Biomedical Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK.}, author = {Jones, Caitlin A A. and McCreary, Andrew C C.}, citeulike-article-id = {3100636}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.neuropharm.2008.05.025}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/18621404}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=18621404}, day = {3}, doi = {10.1016/j.neuropharm.2008.05.025}, issn = {0028-3908}, journal = {Neuropharmacology}, keywords = {5-ht, 5-ht1, 5-ht7, serotonin}, month = {June}, posted-at = {2008-08-08 14:30:41}, priority = {2}, title = {Serotonergic approaches in the development of novel antipsychotics.}, url = {http://dx.doi.org/10.1016/j.neuropharm.2008.05.025}, year = {2008} }

TY - JOUR ID - citeulike:3100636 L3 - citeulike-article-id:3100636 N2 - Schizophrenia is a chronic, debilitating neuropsychological disease characterised by positive, negative, and cognitive deficits. In recent years, new pharmacological treatment strategies have been developed to treat the sequalae of schizophrenia based upon more selective receptor activity profiles in the hope that treatment efficacy can be increased without inducing the side-effect profiles seen with current available therapies. One such strategy involves the development of combined (partial) 5-HT(1A) agonists and D(2) receptor (partial) antagonists such as bifeprunox, SLV313, F15063 and SSR-181507 in an attempt to increase therapeutic efficacy of all symptom domains whilst alleviating adverse side effects. Other novel drugs including SLV310 and SLV314 combine selective serotonin reuptake inhibition (SSRI) functionality with D(2) receptor antagonism in an attempt to not only improve schizophrenic symptoms, but to also relieve other affective disorders intricately linked with the disorder. The main scope of this review will evaluate the major preclinical and clinical pharmacological findings concerning the aforementioned strategies and pharmacological agents, and compare their therapeutic potential with currently available antipsychotics; however, recent developments at other emerging serotonergic targets such as 5-HT(2C), 5-HT(6) and 5-HT(7) receptors will also be considered. JF - Neuropharmacology SN - 0028-3908 AD - Institute of Neuroscience, School of Biomedical Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK. TI - Serotonergic approaches in the development of novel antipsychotics. KW - 5-ht KW - 5-ht1 KW - 5-ht7 KW - serotonin AU - Jones, Caitlin A AU - McCreary, Andrew C PY - 2008/06/03/ UR - http://dx.doi.org/10.1016/j.neuropharm.2008.05.025 ER -